Prothena Corporation PLC (PRTA) was Reiterated by Barclays to “Overweight” according to the research note released today. The brokerage firm has raised the Price Target to $ 70 from a previous price target of $60 . Barclays advised their investors in a research report released on Aug 4, 2016.
Many Wall Street Analysts have commented on Prothena Corporation PLC. Barclays Initiated Prothena Corporation PLC on May 13, 2016 to “Overweight”, Price Target of the shares are set at $60.
On the company’s financial health, Prothena Corporation PLC reported $-1.18 EPS for the quarter, missing the analyst consensus estimate by $ -0.27 based on the information available during the earnings call on Aug 2, 2016. Analyst had a consensus of $-0.91. The company had revenue of $.33 million for the quarter, compared to analysts expectations of $.39 million. The company’s revenue was up 22.2% compared to the same quarter last year.
Prothena Corporation PLC closed down -1.05 points or -1.85% at $55.61 with 2,58,412 shares getting traded on Tusday. Post opening the session at $56.38, the shares hit an intraday low of $54 and an intraday high of $56.5441 and the price fluctuated in this range throughout the day.Shares ended Tusday session in Red.
In a different news, on May 25, 2016, Dennis J. Selkoe (director) sold 5,000 shares at $45.00 per share price. According to the SEC, on Apr 15, 2016, Karin L Walker (officer ) sold 4,000 shares at $45.23 per share price. On Jan 6, 2016, Arthur W Homan (Chief Legal Officer) sold 3,125 shares at $65.50 per share price, according to the Form-4 filing with the securities and exchange commission.
Prothena Corporation Public Limited Company is an Ireland-based late-stage clinical biotechnology company. The Company is focused on the discovery development and commercialization of protein immunotherapy programs for the treatment of diseases that involve amyloid or cell adhesion. The Company’s research and development pipeline includes three therapeutic antibody programs such as NEOD001 for the treatment of AL amyloidosis; PRX002 in collaboration with Roche for the treatment of Parkinson’s disease and other related synucleinopathies and PRX003 for the treatment of psoriasis and other inflammatory diseases. The Company’s pipeline also includes several late discovery stage programs for which it is testing antibodies in preclinical models of diseases related to amyloid or cell adhesion.